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Abstract
We utilized computerized record-linkage methods to link HIV and cancer databases with limited unique identifiers in Pune, India, to
determine feasibility of linkage and obtain preliminary estimates of cancer risk in persons living with HIV (PLHIV) as compared with the
general population.
Records of 32,575 PLHIV were linked to 31,754 Pune Cancer Registry records (1996–2008) using a probabilistic-matching
algorithm. Cancer risk was estimated by calculating standardized incidence ratios (SIRs) in the early (4–27 months after HIV
registration), late (28–60months), and overall (4–60months) incidence periods. Cancers diagnosed prior to or within 3 months of HIV
registration were considered prevalent.
Of 613 linked cancers to PLHIV, 188 were prevalent, 106 early incident, and 319 late incident. Incident cancers comprised 11.5%
AIDS-defining cancers (ADCs), including cervical cancer and non-Hodgkin lymphoma (NHL), but not Kaposi sarcoma (KS), and
88.5% non-AIDS-defining cancers (NADCs). Risk for any incident cancer diagnosis in early, late, and combined periods was
significantly elevated among PLHIV (SIRs: 5.6 [95% CI 4.6–6.8], 17.7 [95% CI 15.8–19.8], and 11.5 [95% CI 10–12.6], respectively).
Cervical cancer risk was elevated in both incidence periods (SIRs: 9.6 [95% CI 4.8–17.2] and 22.6 [95% CI 14.3–33.9], respectively),
while NHL risk was elevated only in the late incidence period (SIR: 18.0 [95% CI 9.8–30.20]). Risks for NADCs were dramatically
elevated (SIR>100) for eye-orbit, substantially (SIR>20) for all-mouth, esophagus, breast, unspecified-leukemia, colon-rectum-
anus, and other/unspecified cancers; moderately elevated (SIR>10) for salivary gland, penis, nasopharynx, and brain-nervous
system, and mildly elevated (SIR>5) for stomach. Risks for 6 NADCs (small intestine, testis, lymphocytic leukemia, prostate, ovary,
and melanoma) were not elevated and 5 cancers, including multiple myeloma not seen.
Our study demonstrates the feasibility of using probabilistic record-linkage to study cancer/other comorbidities among PLHIV in
India and provides preliminary population-based estimates of cancer risks in PLHIV in India. Our results, suggesting a potentially
substantial burden and slightly different spectrum of cancers among PLHIV in India, support efforts to conduct multicenter linkage
studies to obtain precise estimates and to monitor cancer risk in PLHIV in India.
Abbreviations: ADC = AIDS-defining cancers, cART = combination antiretroviral therapy, CIP = combined incidence period
(4–60 months period after HIV registration), EI = early incident (cancers occurring in the 4–27 months period after HIV registration),Editor: Akhilanand Chaurasia.
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HHV-8= human herpes virus 8, ICTC= Integrated Counseling and Testing Centers, KS=Kaposi sarcoma, LI= late incident (cancers
Godbole et al. Medicine (2016) 95:37 Medicineoccurring in the 28–60 months period after HIV registration), MSM = men who have sex with men, NADC = non-AIDS-defining
cancers, NARI = National AIDS Research Institute, NHL = non-Hodgkin lymphoma, PCR = Pune Cancer Registry, PLHIV = persons
living with HIV, SIR = standardized incidence ratio.
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An estimated 2.61 million persons were living with HIV (PLHIV)
in India in 2004 and while this figure was revised down to 2.11 in
2015,[1,2] it still represents about 6% of the global HIV epidemic.
The Government of India has responded to this substantial HIV
epidemic by implementing free combination antiretroviral
therapy (cART), starting in 2004. Today, over 800,000 PLHIV
are currently receiving antiretroviral treatment in India[3] and
longevity among PLHIV has increased as HIV-related mortality
among cART recipients has dramatically declined.[2] However,
the increased longevity of PLHIV has uncovered new threats to
life from chronic complications, including cancer.[4–8] The
relative contribution of cancer to chronic HIV-related comor-
bidity in India is poorly understood.[9] Studies conducted in the
United States, Europe, and Australia reported dramatic increases
in the risk for Kaposi sarcoma (KS), aggressive non-Hodgkin
lymphoma (NHL) and, to a lesser extent, cervical cancer. These
cancers are designated AIDS-defining cancers (ADCs).[5–8] The
risks for several other cancers, including lung, anal, and liver
cancer, were shown to be consistently, albeit modestly, elevated
in PLHIV. Thus, these cancers are designated non-AIDS-defining
cancer (NADCs). Not surprisingly, the use of cART in those
countries has resulted in dramatic reduction of KS and NHL and
concomitant increase in the risk for NADCs in PLHIV living
longer.[10] Although ADCs remain important, NADCs are
becoming more important causes of morbidity and mortality
among PLHIV in those countries.[11]
Whether Indian PLHIV experience similar cancer risks is
currently unknown. An Indian tertiary cancer hospital study[12]
confirmed that cancer is seen in Indian PLHIV,[13] but suggested
that the cancer spectrum in Indian PLHIV may be different from
that reported elsewhere.[9] For example, KS, the classical ADC,
was not seen in that study nor has it been reported as a common
cancer in Indian men who have sex with men (MSM).[14] Primary
central nervous system lymphoma, whose risk is elevated several
hundred-fold in more developed countries, appears not to be
common in Indian PLHIV.[9,14,15] The lack of quantitative data
about cancer risk in Indian PLHIV hampers efforts to address the
cancer burden among PLHIV.[9]
To address this issue, we used computerized probabilistic
record-linkage methods to link records from one HIV/AIDS
registry to records from the Pune Cancer Registry (PCR) in India.
Record-linkage methods are now widely used in developed
countries to rapidly and efficiently generate cancer statistics.[5]
While the record-linkage studies conducted in the United States
rely on the availability of unique personal identifiers (social
security numbers) in the health databases, which are not available
in India, record-linkages have been successfully conducted
without unique personal identifiers in developed countries,
including Italy and[16] Australia.[17] Moreover, they have recently
been successfully used in Uganda, Nigeria and, most recently, in
South Africa.[18–21] The objective of this first computerized
record-linkage study of HIV and cancer in India was to determine2the feasibility of this approach in India, to obtain preliminary
cancer data in PLHIV, and to explore cancer patterns in a
representative sample of PLHIV.
2. Methods
Ethics review boards at National AIDS Research Institute
(NARI), the University of California, Los Angeles, and the
Office of Human Subject Research at the National Institutes of
Health approved the study.
2.1. Study population
The study was conducted in 2011 in Pune, a major city in the
western Indian state of Maharashtra, with a population of
3.12 million in 2011.[22] Pune city was one of the Indian regions
where HIV was recognized early and became a site for many of
the early HIV studies. In addition, its population-based cancer
registry, established in 1972 as an affiliate of theMumbai Cancer
Registry, is one of the oldest cancer registries in India. In 2008, a
study conducted in Pune reported a high HIV prevalence among
high risk populations and pregnant women varying from > 5%
to 74%.[23] PLHIV in Pune have been estimated as 40,000 in
2000[24] and 27,000 in 2008 using different methods.[23] The
National AIDS Research Institute (NARI), which leads national
HIV research programs of the Indian Council of Medical
Research, has provided free HIV testing services in Pune city since
the outset of the epidemic. In addition, HIV Integrated Testing
and Counseling Centers (ICTC), established by the Government
of India, were rapidly expanded since 2005 to implement
free cART in Pune for persons with AIDS/CD4+ cell counts
<200/mm3. These changes increased the percentage of PLHIV
registered at government ICTCs who were on ART from
negligible in 2004 to 37% in 2012.[25] Thus, while this increase
in access to cART is significant, the duration of cART use and
availability is still relatively short to demonstrate temporal trends
due to provision of cART in our linkage study.
The HIV registry of Pune city was constructed using the NARI
data from 1991 to 2008 and the ICTC register data until 2008.
NARI HIV data, which includes unique personal identification
numbers but not the patient names, was computerized to create
the “HIV Serology Database.” Patient information (names, sex,
birthdates/age, residence, and address), unique identification
number, but not the HIV results, which was recorded on paper,
were compiled and computerized to create an electronic
demographic database. This database was linked to the HIV
Serology Database using the unique patient numbers to create the
“NARI HIV-Seropositive Database” (Fig. 1). To ensure
completeness of our HIV database for Pune residents, data on
HIV positive persons from Pune ICTCs were added to the “NARI
HIV-Seropositive Database.” The resulting HIV database, called
the “Pune HIV Database,” was formatted to construct a match
compatible file for the linkage. Because individuals were
registered after being diagnosed as HIV positive, their date of
Figure 1. The flowchart depicts the methodology and outcomes of the computerized HIV database and Cancer Registry Match. Steps for pre-match database
review, cleaning, and preparation resulting inmatch-compatible files are shown. Details of the 4match passes for the computerized linkage are outlined. It ends with
details of the HIV records linked to cancer by time since registration in HIV database including the early incident (EI) and late incident (LI) periods. Cancers diagnosed
before or within 3 months of NARI registration were considered prevalent and were excluded from incidence analysis.
Godbole et al. Medicine (2016) 95:37 www.md-journal.comsero-conversion is not known. Thus, the date of registration was
considered as the date when follow-up of PLHIV started.
Cancer outcomes in PLHIV were based on being linked to a
record in the PCR. PCR uses active and passive registration
of cases. PCR registrars regularly visit cancer hospitals (∼35)
and radiotherapy centers (∼9) in Pune city to identify and
record new cancer cases. Cancer cases from Pune who seek3treatment in Mumbai are registered by the Mumbai
Cancer Registry and their data repatriated to PCR for statistical
analysis. PCR is considered a high quality cancer registry based
on being included in 5 volumes (IV, V, VIII, IX, and X) of the
Cancer Incidence in Five Continents Monograph series[26] and a
survey in 1999 suggested it was 80% complete.[27] For this
analysis, we used PCR data from 1996 to 2008, which were
Table 1
Baseline characteristics of HIV-infected persons registered with the HIV/AIDS Database in Pune, India.
Characteristic HIV-infected persons, N=32,575 HIV-infected persons linked to cancer, N=613
Sex Male 20,865 (64.1%) 335 (54.6%)
Female 11,710 (35.9%) 278 (45.4%)
Age group (years) <14 1,298 (4%) 9 (1.5%)
14–24 5,463 (16.8%) 59 (9.6%)
24–34 14,916 (45.8%) 237 (38.7%)
34–44 7,933 (24.4%) 182 (29.7%)
44–54 2,178 (6.7%) 84 (13.7%)
55 and above 787 (2.4%) 42 (6.9%)
Marital status Unmarried 549 (1.7%) 4 (0.7%)
Married 4,280 (13.1%) 77 (12.6%)
Widowed/divorced/separated 620 (1.9%) 17 (2.8%)
Not reported 27,126 (83.3%) 515 (84%)
Calendar year 1991–1995 2,078 (6.4%) 58 (9.5%)
1996–2000 10,706 (32.9%) 306 (49.9%)
2001–2005 11,380 (34.9%) 131 (21.4%)
2006–2009 8,411 (25.8%) 118 (19.3%)
Total person time by calendar year 1991–1995 9850.63 (8.25%) 255.6 (17.2%)
1996–2000 50,413.77 (42.2%) 1013.8 (68.2%)
2001–2005 47,351.8 (39.66%) 188.2 (12.7%)
2006–2009 11,763.71 (9.85%) 28.1 (1.9%)
The baseline characteristics of HIV-infected persons registered with the HIV AIDS Database in Pune, India (1991–2008) are described along with the distribution of these characteristics among patients linked to
cancer after the match.
Godbole et al. Medicine (2016) 95:37 Medicinecoded using ICD-9 (1996–2005) and ICD-10 codes
(2006–2008). ICD-10 codes were recoded to ICD-9, the
databases were cleaned to construct match-compatible files for
linkage (Fig. 1).
The HIV and cancer match-compatible files had a similar data
structure to facilitate record-linkage. For example, the names in
both were edited to remove spelling errors, titles, and to use
common spelling. In addition, we developed a dictionary of short
forms of the names, based on commonly adopted abbreviations
for long names, for example, Ramakant, Ramesh, Ramu, or
Ramchandra, for use in the match-compatible files. Because
birthdates were often not complete or reported accurately, that is,
day, month, and year, a birth-year group variable called
“birthyear-5” was created with the birth year as the midpoint
for 5-year birth interval.
Computerized probabilistic linkage of records in the match-
compatible HIV and cancer files was done using a matching
algorithm similar to that used in theUS and inUganda.[18] Briefly,
the similarity of records was calculated using harmonized values
or characters of variable names: family and other names, sex, city
PIN code, birth year and/or age at registration as was done in
previousmatches.[18,28] Variables with an exact match received a
perfect score. Variables with inexact matching values (or
characters) were penalized so that the scores were reduced in
proportion to the inexactness, until it was such that the variables
were not similar at all and they made no contribution to the
overall match score. To ensure the record linkage was as
complete as possible, 4 separate match passes were run. To
ensure efficiency of match passes, each pass was implemented
within a block of variables for which the records being matched
had the same exact values. These records were then compared for
on the non-blocking variables (Fig. 1).[28] Records that were
linked in a particular match pass were excluded from the
subsequent pass. All potential matches were reviewed by NARI
staff to select valid matches, based on the similarity of the
original files.42.2. Statistical analysis
Cancers were considered prevalent (present at or before diagnosis)
if they were diagnosed before or within 3 months of NARI
registration. Because of concerns related to surveillance bias
around the time of registration, these cancers were excluded from
incidence analysis (SIR). Cancers were defined as “incident”
cancers if they were diagnosed 4 to 60 months after NARI
registration. This 56-month period is referred to as the “combined
incidence” period (CIP). Cancers in the CIP were further
subdivided into early incident (EI) cancers diagnosed in the 4 to
27 month period after registration and late incident (LI) cancers
diagnosed 28 to 60 months after registration. The risk of specific
cancers in the PLHIV for the early, late, and combined incidence
periods relative to the general population was estimated by
calculating standardized incidence ratios (SIRs) for each cancer
type by dividing the observed number of cancers linked to PLHIV
by the expected number of cancers in the period. The expected
number of cancers in PLHIV was calculated as the sum of the
products of the person-time of PLHIV at risk and the age-group,
sex, and period (1996–2000, 2001–2005, 2006–2008) specific
cancer rate from the general population in Pune city. The person-
time of PLHIV at risk of cancer was calculated from the date of
registration at NARI until cancer diagnosis, date of censoring (60
months from date of registration), or December 31, 2008
(whichever occurred earliest). The significance of SIRs was
assessed by calculating 95% confidence intervals (95% CIs)
assuming that cancer incidence in PLHIV follows a Poisson
distribution. We considered cancers in PLHIV to be statistically
associated with HIV when their SIRs were significantly elevated
both in the early and in the late incident periods. Cancers whose
SIRs were significantly elevated in only one incident period and in
the combined periods were considered to be possibly associated
with HIV, while the cancers whose SIRs were not increased in any
incidence period, were considered not associated with HIV. We
also examined for a statistical trend in the SIRs from the early to the
late incident period for the HIV-associated or possibly associated
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6cancers to determine possible contribution of depth or duration
of immunosuppression using a binomial distribution to compare
SIRs. Two-sided P values <0.05 were considered statistically
significant. Sinceobjectiveswere to test for feasibilityof conducting
computerized linkage of HIV and cancer registries and to obtain
preliminary data, we did not adjust for the multiple comparisons
which allows detailed exploration of the data. This is similar to the
approach used in the Uganda HIV-Cancer registry match study,
which also generated preliminary exploratory data.[18] We did not
adjust for several important risk factors for cancer, such as
prevalent viral coinfections, lifestyle factors, such as smoking and
alcohol consumption, and CD4 T-cell counts, because data for
these variables were incomplete. Statistical analyses were done
using SAS software (Cary, NC) version 9.2.1.3. Results
We linked 32,575 of 44,331 PLHIV from Pune city who had
complete data (Table 1) to 31,754 cancer patients registered in
PCR (Fig. 1). PLHIV males were more likely to be older than
females (32 vs 27 years, P<0.001). We linked 613 PLHIV to
cancers, suggesting that about 1.9% of registered cancers in PCR
might be HIV positive. The linked cancers were designated as
prevalent among 188 individuals. Although excluded from risk
analysis, they are briefly described. They included 139 cancers
diagnosed≥12 months before registration, 32 diagnosed < 12
months before registration, and 17 diagnosed 0 to 3 months of
registration. The prevalent cancers were ADC among 16% of
those diagnosed≥12 months before registration, 13% < 12
months before registration, but 47% among those diagnosed 0 to
3 months after registration.
There were 425 incident cancers, including 106 in the early
incident and 319 in the late incident period (Fig. 1). Most
(81.9%) of the incident cancers were NADCs (Table 2). Table 2
also shows that the risk for any incident cancer diagnosis for
PLHIV in Pune was significantly elevated as compared with the
general population between 4 and 60 months after HIV
registration (SIR: 11.5 [95% CI 10, 12.6]).3.1. AIDS-defining cancers
Consistent with earlier reports from India,[12,29] Kaposi sarcoma
was not observed in PCR. Cervical cancer was observed in 10.4%
and 7.2% of the cancers in the early and late incident periods,
respectively (Table 2, Fig. 2). The risk for cervical cancer was
elevated in both periods and it increased 2.4 times from the early
to the late period (SIR: 9.6 [95% CI 4.8–17.2] and 22.6 [95% CI
14.3–33.9], Ptrend=0.026) (Table 2). NHL was observed in 1%
and 4.4% in the early and late incident periods (Table 2). NHL
risk was elevated in the late, but not early incident period (SIR:
18.0 [95% CI 9.8–30.2] vs 1.6 [95% CI 0–8.7]). The 11-fold
increase in SIR for NHL from the early to the late incident period
was statistically significant (Ptrend=0.003) (Table 2, Fig. 2) and
was observed both among males (13.7, 95% CI 6.3–26.1) and
females (40.9, 95% CI 13.3–95.5), suggesting that this
observation may be valid. The morphologic diagnosis of NHL
was not specified in 15 cases, but was follicular lymphoma in one
case. No case of Burkitt lymphoma was identified.
3.2. Non-AIDS-defining cancers
A wide range of NADCs (13 of 38 evaluated) showed significant
elevations in risk compared with the general population in both
Figure 2. The graphical representation of standardized incidence ratios (SIR) for AIDS-defining cancers along with the 95% Poisson confidence intervals. SIRs
were calculated by dividing the observed number of cancers linked to persons living with HIV (PLHIV) by the expected number of cancers in the period. SIRs with
Godbole et al. Medicine (2016) 95:37 www.md-journal.comthe early and late incidence periods (Fig. 3, Table 2). The risk was
dramatically (SIR>100) elevated for eye-orbit, substantially
elevated (SIR>20) for all-mouth, esophagus, breast, unspecified
leukemia, colon, rectum and anus, and other/unspecified cancers;
and moderately elevated (SIR>10) for salivary gland, penis,
nasopharynx, and brain-nervous system. We observed a small
but statistically significant elevation for stomach (SIR>5). We
observed a statistical trend in the SIR from the early to the late
incident periods for 5 of 13 NADCs that were statistically
associated with HIV infection (colon-rectum-anus, esophagus, all
mouth, breast, and unspecified cancer) (Fig. 3A), but not for the
remaining 6 NADCs (lung-trachea-bronchus; nasopharynx,
stomach, brain-nervous system, salivary gland, penis, unspecified
leukemia, and eye-orbit) (Fig. 3B). Interestingly, the risk for
female breast cancer was elevated in the early and late incident
periods and also showed a statistical trend (SIR: 3.6, [95% CI
1.4–7.3] and 23.6 [95% CI 16.7–32.4] Ptrend<0.001), but these
results are based on 7 and 38 cases, respectively. The mean age at
breast cancer diagnosis was 38.6 years in PLHIV, which was
significantly lower than 54.3 years in women in the general
population (P< .001). Histologically, the linked breast cancers
were duct adenocarcinoma in 71% and 82% of the early and late
incident cases. The risk for all-mouth cancer also showed notable
elevation in the early and late incident periods and strong
statistical trend between the periods (SIR: 4.3 [95% CI 1.9–8.5]
and 27.0 [95% CI 19.7–36.1] Ptrend<0.001), based on 8 and 45
cases, respectively.
There were 12 of 38 NADCs whose risks were significantly
elevated in the late incident and combined periods (Fig. 3-C). Of
these, risk was substantially elevated for peritoneum and
retroperitoneum (42.8, 95% CI 5.2–154.6) and uterus (63.5,
95% CI 20.6–148.1). The results for uterine cancer were based
on 6 cases, including 3 endometrial adenocarcinoma, 2
squamous-cell type and 1 unspecified uterine cancer, probably7misclassified squamous cell carcinoma of the cervix. SIRs were
modestly elevated for gall bladder and extra hepatic biliary ducts
(20.1, 95% CI 4.1–58.7), pancreas (14.7, 95% CI 4.0–37.7),
kidney, renal pelvis, ureter, and urinary bladder (15.7, 95% CI
7.2–29.7), myeloid leukemia (17.6, 95% CI 8.0–33.4), and other
non-epithelial skin (31.2, 95% CI 11.5–68.0). SIRs were slightly
elevated for other pharynx (9.9, 95% CI 3.2–23.2), Hodgkin
lymphoma (10.5, 95% CI 2.2–30.6), connective and soft tissue
including heart (10.0, 95%CI 3.2–23.2), and liver (14.9, 95%CI
6.0–30.7). The liver cases included 5 with hepatocellular
carcinoma, 1 each of adenocarcinoma, cholangiocarcinoma,
and unspecified neoplasm. The results for Hodgkin lymphoma
were based on 4 cases whose subtype was not specified.
Pleura/mesothelioma, peripheral nerves, vulva, placenta, and
multiple myeloma were not seen in PLHIV. SIR for thyroid (14.1,
95%CI 3.8–36.1) and vaginal (49.0, 95%CI 5.9–177.0) cancers
were elevated only in the early incidence period.4. Discussion
We tested the feasibility of applying computerized probabilistic
record-linkage methods to study the burden and spectrum of
cancer in Indian PLHIV as a proof-of-concept. Our results
demonstrate the feasibility of this approach. We also provide
detailed preliminary estimates of the impact of HIV on cancers
seen in a well-defined population of PLHIV in India. Our
findings, based on data from one city in India, point to a
substantial burden of cancer in Indian PLHIV. They suggest that
PLHIV may contribute to about 1.9% of cancers in the general
population and that the SIR of cancer in PLHIV is elevated about
11.5-fold compared with the general population. In contrast to
findings in linkage studies conducted in Africa, which have shown
ADCs as the major cancers,[18,19,21] NADCs appear to
predominate in Indian PLHIV.
Figure 3. The figure includes four panels each showing graphical representation of standardized incidence ratio (SIR) in the early (EI) and late incidence (LI) periods
with 95% Poisson confidence intervals for different non-AIDS-defining cancers among persons living with HIV (PLHIV) in Pune. SIRs are plotted on a logarithmic
scale. (A) Depicts SIR for cancers that are significantly associated with HIV in both early and late incidence periods and additionally shows a significantly increasing
trend from early to late periods.
∗
P (trend) values are: breast (P<0.001), mouth (P<0.001), esophagus (P=0.007), colon (P=0.002), unspecified cancers (P=
0.001). (B) Depicts SIRs for cancers that are also significantly associated with HIV in both early and late incidence periods; however, they do not show increasing
trend from early to late periods. Note: SIR for eye and orbit (shown in table 2) is not shown in this figure. (C) Depicts SIRs in early and late incidence periods for
cancers that are significantly raised in late and combined incidence periods and therefore considered to be possibly associated with HIV (data for combined period
is shown in Table 2). However, they do not show increasing trend from early to late periods. (D) Depicts the SIRs for cancers which are not significantly elevated in
either the early or late periods and are hence considered “not associated” with HIV.
Godbole et al. Medicine (2016) 95:37 MedicineOur results also suggest some differences in the spectrum of
cancer in Indian PLHIV compared with PLHIV from developed
countries.[5,7,10,16–19] For example, KS was absent and the risk
for cervical, conjunctival, and breast cancer were substantially
elevated. The absence of KS in Indian PLHIVmirrors results from
anecdotal and case series reports and it is consistent with the
absence of KS in the general population in Pune city.
Interestingly, 15% to 25% HIV-infected males in Northern
India were Kaposi sarcoma-associated herpes virus (KSHV)
positive,[30] but local data for Pune are not available. NHL
(1–4.4%) and cervical cancer (7–10.5%) risks were elevated in
Indian PLHIV, in accord with Dhir et al.[12] Although comparing
with data from other countries is risky, NHL risk in Indian
PLHIV appears to be lower than the risk observed among PLHIV
in the United States before widespread use of HAART,[5] and
cervical cancer risk was higher than has been reported in Uganda
and Nigeria.[18,19] The risks for cervical cancer are concerning
given reports of high prevalence of cervical high-risk HPV and
precancerous abnormalities among women living with HIV
(WLHIV) in India.[31–33] At the time when the study was
conducted, routine cervical cancer screening was not an ingrained
standard of care for either PLHIV or women in general8population. Since India has one of the highest cervical cancer
burdens worldwide,[34] and about 40% of the estimated 2.1
million PLHIV in India are women,[2] our results highlight a
potential cervical cancer burden in patients living longer on cART
and an opportunity to intensify or strengthen cervical cancer
screening for WLHIV in India.
The reasons for increased cancer risk among PLHIV may
include high prevalence of oncogenic viruses in PLHIV, relatively
low use of cART, chronic inflammation/immune activation, and
lifestyle factors, such as smoking and alcohol consumption.[35]
Our estimates may be biased because we lacked data on
confounders for proper adjustment, but they provide motivation
to conduct hypothesis-driven studies to delineate causal factors,
as is being conducted in the United States and elsewhere.
We found that SIRs for 13 NADCs, which are linked to
infectious etiology (mouth, salivary glands, nasopharyngeal
carcinoma, esophagus, stomach, anus, penis, and eye or orbit),
or to lifestyle risk factors, such as smoking or chewing betel nut,
(lung, bronchus, and mouth), were elevated. If confirmed in
larger series, these findings may support development of public
health messages to stress the prevention of cancer among PLHIV
using cost-effective screening programs to reduce cancer
[36,37]
Godbole et al. Medicine (2016) 95:37 www.md-journal.commorbidity and mortality. Similarly, our findings that 47%
of cancers occurring during the first 3 months after registration
are ADC suggest that evaluation of cancer at the time of HIV
registration could lead to improved clinical outcomes among
PLHIV.
Our finding of dramatically elevated risk for eye cancers is
based on small numbers, but it is notable because similar results
have been reported from south India[38] and in PLHIV in
Africa[21,39,40] and in the United States.[41] Exposure to
ultraviolet light is implicated, but the role of infections is
controversial.[41–43] Our finding of increased risk of breast cancer
in Indian PLHIV was unexpected, but is similar to one report
fromUganda[18] and inWest Africa,[19] but different from reports
in developed countries.
The strengths of our study include using a high quality
population-based cancer registry and a well-defined HIV
population to study the spectrum of cancers in PLHIV in India
using a computerized probabilistic-record linkage. This method
has become a standard in developed countries including Italy,
Australia, the United States, and European countries and is being
vigorously applied in several countries in Africa.
The limitations of our study include a relatively small sample
size, which resulted in relatively imprecise estimates, and focusing
on PLHIV from one region of India.
Surveillance bias may be a factor in our results, but stigma and
poverty could limit access to cancer diagnosis and lead to under
ascertainment of cancers. We believe surveillance bias might not
be substantial because of less awareness of cancer complications
among the PLHIV in India. As a previous Indian study
suggests,[12] as many as 50% or more of people with HIV and
cancer were not aware of HIV status, while about a third of all
cancers linked in our study were diagnosed before HIV diagnosis.
We acknowledge the possibility of imperfect/missed linkages,
undiagnosed cases, or improperly completed records, and our
results should be interpreted with some caution. However, our
results should be comparable to those performed in other
countries without unique personal identity numbers.[18]
In conclusion, our study highlights the feasibility of using
computerized match studies to obtain timely data on the cancer
burden among PLHIV in India. This report thus provides
departure point for initiating a public health dialogue on the
unique opportunity to leverage the wide network of free
government-funded antiretroviral treatment centers and integrate
systematic cancer screening among PLHIV in India.
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